GlassScriptPhysician profile
Paul Q Cerny
NPI 1093707473
$3,863.95
in general payments reported to CMS, 2019-2025
40 companies · $334 in 2025
The $334 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,567 · 2020: $613 · 2022: $356 · 2023: $299 · 2024: $696 · 2025: $334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,328.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,328.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $804.82 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $507.39 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $481.79 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $270.01 | 2019-2025 | Jardiance, Tradjenta |
| Abbvie INC. | $235.73 | 2022-2025 | Qulipta, Vraylar, Ubrelvy |
| Glaxosmithkline, LLC. | $145.88 | 2019-2023 | Shingrix, Bexsero, Menveo |
| Abbott Laboratories | $143.73 | 2019-2024 | Freestyle Libre 3 |
| Lilly USA, LLC | $129.97 | 2019-2025 | Zepbound, Mounjaro |
| Merck Sharp & Dohme LLC | $127.12 | 2019-2020 | |
| Amgen INC. | $100.81 | 2019-2025 | Repatha |
| Dexcom, INC. | $78.92 | 2023-2025 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $67.58 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $59.79 | 2019 | |
| Novartis Pharmaceuticals Corporation | $58.68 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $48.33 | 2019-2020 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Cerny listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.